

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Ferrer International (inhaled)	All Wales Therapeutics and Toxicology
treprostinil)	Centre
а эргээнш)	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Action for Pulmonary Fibrosis	Wales
Asthma and Lung UK	British National Formulary
Blood Pressure UK	Care Quality Commission
British Cardiac Patients Association	Department of Health - Northern Ireland
British Cardiovascular Society	Healthcare Improvement Scotland
Cardiovascular Care Partnership	Medicines and Healthcare products
Circulation Foundation	Regulatory Agency
Heart UK	National Association of Primary Care
NARA - The Breathing Charity	National Pharmacy Association
Network of Sikh Organisations	NHS Confederation
Pulmonary Hypertension Association	Scottish Medicines Consortium
UK	Welsh Government
 Pumping Marvellous Foundation 	Welsh Health Specialised Services
 Scleroderma & Raynaud's UK 	Committee
Somerville Foundation	
South Asian Health Foundation	Possible comparator companies
Specialised Healthcare Alliance	Advanz Pharma (epoprostenol,
	nifedipine, warfarin)
Healthcare professional groups	Aguettant (nicardipine)
Association of Respiratory Nurse	Amarox (amlodipine, sildenafil)
Specialists	AOP Orphan (intravenous treprostinil)
British and Irish Hypertension Society	Aspen (digoxin)
British Association for Nursing in	Aurobindo Pharma – Milpharm
Cardiovascular Care	(amlodipine, bosentan, sildenafil)
British Geriatrics Society	Bayer (inhaled iloprost, nifedipine)
British Heart Foundation	Brillpharma Limited (amlodipine)
British Nuclear Cardiology Society	Bristol Laboratories (amlodipine)
British Society for Haematology	Brown and Burk UK (tadalafil)
British Society for Heart Failure	Chiesi (nifedipine)
British Society of Cardiovascular	Cipla EU (ambrisentan, bosentan)
Imaging	Daiichi Sankyo UK (amlodipine)

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459



Provisional Consultees

- British Thoracic Society
- ILD-IN: Interstitial Lung Diseases Interdisciplinary Network
- National Heart and Lung Institute
- Primary Care Cardiovascular Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science and Technology
- Society for Vascular Nurses
- Society for Vascular Technology
- UK Clinical Pharmacy Association
- Vascular Society of Great Britain and Ireland

Others

- Department of Health and Social Care
- NHS England


Provisional Commentators (no right to submit or appeal)

- Dexcel Pharma (nifedipine)
- Dr Reddy's Laboratories (amlodipine, bosentan, intravenous treprostinil)
- Eli Lilly (tadalafil)
- Ethypharm UK Ltd (diltiazem)
- FDC International (amlodipine)
- Galen Limited (diltiazem)
- Genus Pharmaceuticals (nifedipine)
- GlaxoSmithKline UK (ambrisentan, epoprostenol)
- Ipca Laboratories UK (amlodipine)
- Janssen-Cilag (epoprostenol, macitentan, selexipag)
- Krka UK (amlodipine)
- Merck, Sharp & Dohme UK (riociguat, sotatercept)
- Mylan (ambrisentan, amlodipine, bosentan, tadalafil)
- Napp Pharmaceuticals Limited (diltiazem)
- Novartis Pharmaceuticals UK (amlodipine)
- Ranbaxy (epoprostenol, warfarin)
- Rosemont Pharmaceuticals (amlodipine, sildenafil)
- Sandoz (amlodipine)
- Sanofi (diltiazem)
- Strides Pharma (warfarin)
- Teofarma (nifedipine)
- Thame Laboratories (amlodipine)
- Thornton & Ross (diltiazem, nifedipine)
- Tillomed Laboratories (intravenous treprostinil, nifedipine)
- Upjohn UK (amlodipine, sildenafil)
- Zentiva (amlodipine, diltiazem, inhaled iloprost)

Relevant research groups

- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Dept, Barts
- Circulation Foundation
- Cochrane Heart Group
- Cochrane Hypertension Group

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459 Issue date: November 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Cochrane Vascular European Council for Cardiovascular Research Genomics England Heart Research UK MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Institute for Health Research Wellcome Trust
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).





Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.